15 Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis

Qi Zhuang Siah, Tiffany Ts Ye, Benjamin Yong‐Qiang Tan, Jamie Sin Ying Ho, Nicholas Syn, Yao Hao Teo, James Yip, Tiong‐Cheng Yeo, Weiqin Lin, Raymond Wong, Ping Chai, Bernard P.l. Chan, Vijay K. Sharma, Leonard L.l. Yeo, Ching‐Hui Sia2022 · DOI

Introduction

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac condition characterized by abnormal thickening of the heart muscle, which can impede blood flow and predispose patients to serious complications. Among the most concerning risks are acute cerebrovascular events, including ischaemic stroke, transient ischaemic attack (TIA), and systemic thromboembolism. While HCM itself increases these risks, the presence of atrial fibrillation (AF)—a common irregular heart rhythm—is known to worsen the prognosis. This systematic review and meta-analysis seeks to quantify the incidence of these events and evaluate the specific impact of AF on the HCM patient population.

Methodology

Researchers conducted a comprehensive meta-analysis by synthesizing data from 35 previously published articles, encompassing a total of 42,570 patients. The study queried major medical databases (PubMed, Scopus, Embase, and Cochrane) for literature published up to March 2021.

The primary objective was to compare the incidence of ischaemic strokes, TIAs, and systemic thromboembolism in HCM patients with AF versus those without. Statistical analysis was performed using StataSE 16, calculating pooled incidence and Risk Ratios (RR). Heterogeneity across the studies was assessed using the $I^2$ test to determine the consistency of the findings.

Key Findings

The AF "Risk Multiplier"

The most significant finding of the study is that AF acts as a primary driver of neurological events in HCM patients. The analysis revealed that HCM patients with concomitant AF are 3.26 times more likely to experience a stroke or TIA compared to those without the arrhythmia (RR 3.26, 95% CI 1.75–6.08, p<0.001).

Overall Incidence Rates

Across the 24 studies that specifically provided stroke/TIA data (n=37,643), the pooled incidence of these events was 7.45% (95% CI: 5.80–9.52%). This baseline risk underscores the inherent vulnerability of the HCM population to thromboembolic complications.

Apical HCM Subgroup

The study also addressed the risk profile of apical HCM—a variant where thickening occurs at the tip of the heart. Contrary to some clinical perceptions that this subtype might be lower risk, the study found an incidence rate of 9.30% (95% CI 6.64–12.87%). This suggests that patients with apical HCM carry a similar, if not slightly higher, burden of acute cerebrovascular events as the broader HCM population.

Discussion and Clinical Implications

The high statistical significance of the findings regarding AF provides strong evidence for aggressive stroke prevention strategies. Early detection of AF and the timely initiation of anticoagulation therapy are essential for mitigating the tripled risk of stroke in these patients.

Furthermore, the data regarding apical HCM indicates that morphological variants should not lead to a lower clinical suspicion of thromboembolic risk. All HCM patients, regardless of subtype, require careful monitoring for arrhythmias and associated ischaemic risks.

Limitations

The study noted high heterogeneity ($I^2 = 76.0$), indicating significant variation in how different studies reported their findings. This variation may stem from differences in study design, patient demographics, or the definitions used for thromboembolic events. Additionally, some studies did not specify the exact type of thromboembolic event, which may mask nuances between different types of clots. Future research should aim for more standardized reporting to further refine these risk models.

Summary updated

Abstract

<h3>Introduction/Objectives</h3> Hypertrophic cardiomyopathy predisposes to acute cerebrovascular events including ischaemic stroke, transient ischaemic attack and systemic thromboembolism. Atrial fibrillation confers even higher risk. We aim to report the incidence of these complications and to investigate the impact of atrial fibrillation on the prognosis of patients with hypertrophic cardiomyopathy. <h3>Methods</h3> A literature search was performed on PubMed, Scopus, Embase/ Ovid and Cochrane library from inception to 20th March 2021. We compared the incidence of ischaemic strokes, transient ischaemic attack, non-specified thromboembolism events and systemic thromboembolism in hypertrophic cardiomyopathy patients with or without atrial fibrillation. Non-specified thromboembolism events in our paper referred to thromboembolic events whereby their types were not specified in the studies. Meta-analysis was performed using StataSE 16 software, and heterogeneity was assessed using I<sup>2</sup> test. <h3>Results</h3> A total of 713 studies were identified. Thirty-five articles with 42,570 patients were included. The pooled incidence of stroke/ transient ischaemic attack was 7.45% (95% confidence interval [CI] 5.80–9.52, p&lt;0.001) across 24 studies with a total of 37,643 hypertrophic cardiomyopathy patients. Atrial fibrillation significantly increased the risk of total stroke/ transient ischaemic attack (Risk Ratio 3.26, 95% CI 1.75–6.08, p&lt;0.001, I<sup>2</sup> = 76.0). The incidence of stroke/ transient ischaemic attack was 9.30% (95% CI 6.64–12.87, p=0.316) in the apical hypertrophic cardiomyopathy subgroup. <h3>Conclusions</h3> Concomitant atrial fibrillation in hypertrophic cardiomyopathy increases the risk of thromboembolic events including ischaemic stroke and transient ischaemic attack. The apical subgroup shows a similar risk of acute cerebrovascular events as the overall hypertrophic cardiomyopathy population. <h3>Conflict of Interest</h3> None
BibTeX
@misc{siah2022ischaemic,
  author = {Qi Zhuang Siah and Tiffany TS Ye and Benjamin Yong‐Qiang Tan and Jamie Sin Ying Ho and Nicholas Syn and Yao Hao Teo and Yao Neng Teo and James Yip and Tiong‐Cheng Yeo and Weiqin Lin and Raymond Wong and Ping Chai and Bernard P.L. Chan and Vijay K. Sharma and Leonard L.L. Yeo and Ching‐Hui Sia},
  title = {{15 Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis}},
  year = {2022},
  doi = {10.1136/heartjnl-2022-bcs.15},
}
Figure